The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of treatment line on outcomes with salvage ipilimumab + nivolumab in metastatic renal cell carcinoma (mRCC).
 
Ritesh Kotecha
No Relationships to Disclose
 
Chung-Han Lee
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Calithera Biosciences; Eisai
 
Andrea Knezevic
No Relationships to Disclose
 
Neil J. Shah
Honoraria - Castle Biosciences; Castle Biosciences
 
Maria Isabel Carlo
Consulting or Advisory Role - Pfizer
Other Relationship - Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Darren R. Feldman
Research Funding - Astellas Pharma; Decibel Therapeutics (Inst); Novartis; Seagen
Other Relationship - UpToDate
 
Sujata Patil
No Relationships to Disclose
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
Martin H Voss
Stock and Other Ownership Interests - CellGenix (I)
Consulting or Advisory Role - Alexion Pharmaceuticals; Calithera Biosciences; Corvus Pharmaceuticals; Eisai; Exelixis; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Genentech/Roche; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Takeda